Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Phathom Pharmaceuticals (PHAT) Change in Receivables (2023 - 2025)

Historic Change in Receivables for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $4.5 million.

  • Phathom Pharmaceuticals' Change in Receivables fell 5543.98% to $4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.7 million, marking a year-over-year increase of 6500.57%. This contributed to the annual value of $37.2 million for FY2024, which is 217000.61% up from last year.
  • According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Change in Receivables is $4.5 million, which was down 5543.98% from $14.9 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' Change in Receivables' 5-year high stood at $17.7 million during Q4 2024, with a 5-year trough of -$2.4 million in Q1 2025.
  • Moreover, its 3-year median value for Change in Receivables was $5.8 million (2024), whereas its average is $7.0 million.
  • Its Change in Receivables has fluctuated over the past 5 years, first skyrocketed by 98399.51% in 2024, then plummeted by 20847.08% in 2025.
  • Over the past 3 years, Phathom Pharmaceuticals' Change in Receivables (Quarter) stood at $1.6 million in 2023, then soared by 984.0% to $17.7 million in 2024, then crashed by 74.45% to $4.5 million in 2025.
  • Its Change in Receivables was $4.5 million in Q3 2025, compared to $14.9 million in Q2 2025 and -$2.4 million in Q1 2025.